For instance, Green and coworkers[56] reported that nicotinamide’s inhibitory effect on class III NAD(+)-dependent HDACs rescued cognitive deficits in a transgenic mouse model of AD through a mechanism involving the increased acetylation alpha-tubulin and MAP2c and reduced Thr231-phospho-tau. The gene discussed is MAPT; the disease is Alzheimer disease.